"Fluconazole" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
| Descriptor ID |
D015725
|
| MeSH Number(s) |
D03.383.129.799.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluconazole".
Below are MeSH descriptors whose meaning is more specific than "Fluconazole".
This graph shows the total number of publications written about "Fluconazole" by people in this website by year, and whether "Fluconazole" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluconazole" by people in Profiles.
-
Samukawa S, Yoshimi R, Kojitani N, Uzawa Y, Takase-Minegishi K, Kirino Y, Soejima Y, Kato H, Nakajima H. Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report. J Infect Chemother. 2023 Mar; 29(3):347-352.
-
Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD. Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022 04 13; 74(Suppl_2):S162-S168.
-
Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. J Low Genit Tract Dis. 2018 Oct; 22(4):382-386.
-
Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018 06; 218(6):624.e1-624.e9.
-
Powell AM, Gracely E, Nyirjesy P. Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. J Low Genit Tract Dis. 2016 Jan; 20(1):85-9.
-
Katragkou A, Alexander EL, Eoh H, Raheem SK, Roilides E, Walsh TJ. Effects of fluconazole on the metabolomic profile of Candida albicans. J Antimicrob Chemother. 2016 Mar; 71(3):635-40.
-
Katragkou A, McCarthy M, Alexander EL, Antachopoulos C, Meletiadis J, Jabra-Rizk MA, Petraitis V, Roilides E, Walsh TJ. In vitro interactions between farnesol and fluconazole, amphotericin B or micafungin against Candida albicans biofilms. J Antimicrob Chemother. 2015 Feb; 70(2):470-8.
-
Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD. UPC2A is required for high-level azole antifungal resistance in Candida glabrata. Antimicrob Agents Chemother. 2014 Aug; 58(8):4543-54.
-
Steier Z, Vermitsky JP, Toner G, Gygax SE, Edlind T, Katiyar S. Flucytosine antagonism of azole activity versus Candida glabrata: role of transcription factor Pdr1 and multidrug transporter Cdr1. Antimicrob Agents Chemother. 2013 Nov; 57(11):5543-7.
-
Kulkarni MM, Reddy N, Gude T, McGwire BS. Voriconazole suppresses the growth of Leishmania species in vitro. Parasitol Res. 2013 May; 112(5):2095-9.